New drug combo aims to boost lung cancer treatment
NCT ID NCT06116786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-86974680 (an A2a receptor antagonist) and cetrelimab (an immunotherapy drug)
What this could lead to
If successful, this could help identify a safe dose of a new drug combination that may improve treatment options for advanced lung cancer.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to show benefit in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite Research Organisation GmbH
COMPLETEDBerlin, 12203, Germany
-
City of Hope 1
RECRUITINGNewnan, Georgia, 30265, United States
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Hosp Univ Vall D Hebron
RECRUITINGBarcelona, 8035, Spain
-
Hosp. Univ. 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hosp. Univ. I Politecni La Fe
RECRUITINGValencia, 46026, Spain
-
Hosp. Univ. Quiron Dexeus
RECRUITINGBarcelona, 08028, Spain
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Severance Hospital Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Universitaetsklinikum Giessen und Marburg GmbH
RECRUITINGGiessen, 35392, Germany